Teva Once Again Lays Out Case For a Deal With Mylan

Teva Pharmaceuticals Industries Ltd. on Tuesday unveiled its latest attempt to persuade Mylan N.V. of the merits of its proposed $82 a share takeover of the company. In a statement, the Israeli company said it is willing to meet with Mylan and its advisors immediately. "Teva's proposal is extremely attractive for Teva and Mylan stockholders and all other stakeholders," said the statement. "The proposed combination makes compelling strategic, financial and cultural sense." Teva further believes that the regulatory and antitrust issues of the combination can be completed in 2015. Mylan has rejected the Teva bid and last week made a third offer for Perrigo Co. for more than $34 billion, which was rejected. Teva said its own proposal is contingent on Mylan not completing the proposed deal for Perrigo or any other transaction. Mylan shares rose 0.5% in premarket trade, while Teva was up 0.1%.